期刊
ENDOCRINE PRACTICE
卷 23, 期 2, 页码 207-238出版社
ELSEVIER INC
DOI: 10.4158/EP161682.CS
关键词
-
资金
- AstraZeneca
- Janssen Pharmaceuticals, Inc.
- Lexicon Pharmaceuticals, Inc.
- Merck Co.
- Novo Nordisk
- Sanofi
- Amgen
- Boehringer Ingelheim
- Takeda
- Janssen
- Eli Lilly
- Eisai
- Asahi
- Abbott
- Endo Barrier
- Bayer
- Gilead
- Merck
- Weight Watchers
- Lexicon
- Pfizer
- Elcelyx
- Medtronic
- Regeneron
- BI
- Esperion
- Grifols
- Hamni
- GlaxoSmithKline
- Novartis
- Dexcom
- Bristol Myers Squibb
- Ionis
- Orexigen
This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据